Vlad Taru

Vlad Taru

Auto-generated profile, based on publicly available information

Vlad Taru

Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2024 in Journal of Hepatology
Verified
Journal Article
Open access
VTVlad Taru
Vlad Taru
GSGyongyi Szabo
Gyongyi Szabo
WMWajahat Mehal
Wajahat Mehal
TRThomas Reiberger
Thomas Reiberger
Chronic liver disease leads to hepatocellular injury that triggers a pro-inflammatory state in several parenchymal and non-parenchymal hepatic cell types, ultimately resulting in liver fibrosis, cirrhosis, portal hypertension and liver failure. Thus, an improved understanding of inflammasomes - as key molecular drivers of liver injury - may result in the development of novel diagnostic or prognostic biomarkers and effective therapeutics. In liver disease, innate immune cells respond to hepatic insults by activating cell-intrinsic inflammasomes via toll-like receptors and NF-κB, and by releasing pro-inflammatory cytokines (such as IL-1β, IL-18, TNF-α and IL-6). Subsequently, cells of the adaptive immune system are recruited to fuel hepatic inflammation and hepatic parenchymal cells may undergo gasdermin D-mediated programmed cell death, termed pyroptosis. With liver disease progression, there is a shift towards a type 2 inflammatory response, which promotes tissue repair but also fibrogenesis. Inflammasome activation may also occur at extrahepatic sites, such as the white adipose tissue in MASH (metabolic dysfunction-associated steatohepatitis). In end-stage liver disease, flares of inflammation (e.g., in severe alcohol-related hepatitis) that spark on a dysfunctional immune system, contribute to inflammasome-mediated liver injury and potentially result in organ dysfunction/failure, as seen in ACLF (acute-on-chronic liver failure). This review provides an overview of current concepts regarding inflammasome activation in liver disease progression, with a focus on related biomarkers and therapeutic approaches that are being developed for patients with liver disease.

31 May 2024 in Journal of Hepatology
Verified
Journal Article
Open access
RPRafael Paternostro
Rafael Paternostro
WKWilhelmus J. Kwanten
Wilhelmus J. Kwanten
BHBenedikt Silvester Hofer
Benedikt Silvester Hofer
GSGeorg Semmler
Georg Semmler
ABAli Bagdadi
Ali Bagdadi
TRThomas Reiberger
Thomas Reiberger
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of advanced chronic liver disease (ACLD). Portal hypertension drives hepatic decompensation and is best diagnosed by hepatic venous pressure gradient (HVPG) measurement. Here we investigate the prognostic value of HVPG in compensated (cACLD) MASLD. This European multicentre study included MASLD-cACLD patients characterised by HVPG at baseline. Hepatic decompensation (variceal bleeding/ ascites/hepatic encephalopathy) and liver-related mortality were considered the primary events of interest. 340 MASLD-cACLD patients [56.2% men; age: 62 (55-68) years; MELD: 8 (7-9); 71.2% diabetes] were included. Clinically significant portal hypertension (CSPH; i.e., HVPG ≥10 mmHg) was found in 209 patients (61.5%). During a median follow-up of 41.5 (27.5-65.8) months, 65 patients developed hepatic decompensation with a cumulative incidence of 10.0% after 2 years (2Y) and 30.7% after 5 years (5Y) in MASLD-cACLD with CSPH, compared to 2.4% after 2Y and 9.4% after 5Y in patients without CSPH. Variceal bleeding did not occur without CSPH. CSPH (subdistribution hazard ratio, SHR:5.13; p<0.001) was associated with an increased decompensation risk and a higher HVPG remained an independent risk factor in the multivariable model (aSHR per mmHg:1.12; p<0.001). Liver-related mortality occurred in 37 patients with a cumulative incidence of 3.3% after 2Y and 21.4% after 5Y in CSPH. Without CSPH, the incidence after 5Y was 0.8%. Accordingly, a higher HVPG was also independently associated with a higher risk of liver-related death (aSHR per mmHg:1.20; p<0.001). HVPG measurement is of high prognostic value in MASLD-cACLD. While MASLD-cACLD patients without CSPH show a very low short-term risk of decompensation and liver-related mortality is rare, the presence of CSPH substantially increases both risks. While the incidence of compensated advanced chronic liver disease (cACLD) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide, insights into the impact of clinically significant portal hypertension (CSPH) on the risk of liver-related events in MASLD-cACLD remain limited. Based on the findings of this European multicentre study including 340 MASLD-cACLD, we could show that increasing HVPG values and the presence of CSPH in particular were associated with a significantly higher risk of first hepatic decompensation and liver-related mortality. In contrast, the short-term incidence of decompensation in MASLD-cACLD patients without CSPH was low and the risk of liver-mortality remained negligible. Thus, HVPG measurements can provide important prognostic information for individualised risk-stratification in MASLD-cACLD and may help facilitate the study of novel and promising treatment possibilities for MASLD.

19 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MTMadalina-Gabriela Taru
Madalina-Gabriela Taru
LNLidia Neamti
Lidia Neamti
VTVlad Taru
Vlad Taru
Lucia Maria ProcopciucLucia Maria Procopciuc
Lucia Maria Procopciuc
BPBogdan Procopet
Bogdan Procopet
Monica Lupsor-PlatonMonica Lupsor-Platon
Monica Lupsor-Platon
Non-alcoholic fatty liver disease (NAFLD), and its progressive form, non-alcoholic steatohepatitis (NASH), represent, nowadays, real challenges for the healthcare system. Liver fibrosis is the most important prognostic factor for NAFLD, and advanced fibrosis is associated with higher liver-related mortality rates. Therefore, the key issues in NAFLD are the differentiation of NASH from simple steatosis and identification of advanced hepatic fibrosis. We critically reviewed the ultrasound (US) elastography techniques for the quantitative characterization of fibrosis, steatosis, and inflammation in NAFLD and NASH, with a specific focus on how to differentiate advanced fibrosis in adult patients. Vibration-controlled transient elastography (VCTE) is still the most utilized and validated elastography method for liver fibrosis assessment. The recently developed point shear wave elastography (pSWE) and two-dimensional shear wave elastography (2D-SWE) techniques that use multiparametric approaches could bring essential improvements to diagnosis and risk stratification.

21 December 2024 in United European Gastroenterology Journal
Verified
Journal Article
Open access
BHBenedikt Silvester Hofer
Benedikt Silvester Hofer
BSBenedikt Simbrunner
Benedikt Simbrunner
PKPhilipp Königshofer
Philipp Königshofer
KBKsenia Brusilovskaya
Ksenia Brusilovskaya
OPOleksandr Petrenko
Oleksandr Petrenko
TRThomas Reiberger
Thomas Reiberger
Background: Portal hypertension (PH) resulting from static and dynamic intrahepatic changes drives liver‐related complications even after removing the underlying aetiological factor.Objective: We investigated the impact of inflammation on the dynamic component of PH during disease regression in animal models of toxin‐induced cirrhosis and patients with alcohol‐related cirrhosis.Methods: In mice, cirrhosis was induced via toxin application for 12 weeks followed by toxin‐withdrawal allowing for one or 2 weeks of regression. Furthermore, 128 patients with alcohol‐related cirrhosis and alcohol abstinence undergoing same‐day hepatic venous pressure gradient (HVPG) and liver stiffness measurement (LSM) were included. The influence of inflammation on the dynamic PH component was assessed using linear models. Specifically, we explored proinflammatory changes in mice/patients in whom the measured portal pressure (PP)/HVPG was significantly higher than the PP/HVPG expected from the static PH component (histological collagen proportionate area [CPA; %] in mice, LSM in patients).Results: In mice, toxin discontinuation induced a significant decrease in PP, CPA, histological hepatic inflammation and hepatic expression of proinflammatory genes (Tnfa, Il6, Cxcl1, Mcp1; all p < 0.05 for one/2 week regression vs. peak disease). Similarly, prolonged abstinence in alcohol‐related cirrhosis was linked to lower HVPG/LSM and longer abstinence was correlated to lower C‐reactive protein (CRP), IL‐6, immunoglobulin A (IgA) and IgG levels (all p < 0.05). Nevertheless, the persistence of a low‐grade proinflammatory state during regression was linked to a higher PP/HVPG than expected from static PH components. In regressive mice, higher hepatic proinflammatory gene expression (Tnfa, Il6, Il1b; all p < 0.05) was linked to higher‐than‐expected PP. Similarly, higher CRP, IL‐6, IgA and IgG and lower complement factor C3c (all p < 0.05) were associated with higher‐than‐expected HVPG in abstinent patients with alcohol‐related cirrhosis.Conclusions: Although removing the underlying aetiological factor resulted in significant improvements, a persistent hepatic proinflammatory environment remained a key driver of the dynamic PH component in regressive liver disease.Clinical trial number: NCT03267615.

23 September 2025 in Liver International
Verified
Journal Article
Open access
VTVlad Taru
Vlad Taru
GKGeorg Kramer
Georg Kramer
BHBenedikt Silvester Hofer
Benedikt Silvester Hofer
NDNina Dominik
Nina Dominik
LBLorenz Balcar
Lorenz Balcar
BSBenedikt Simbrunner
Benedikt Simbrunner
Background and Aims: The impact of portal hypertension (PH) during acute‐on‐chronic liver failure (ACLF) remains unclear. This study investigated the link between underlying PH severity, systemic inflammation (SI), and the course of ACLF. Methods: Consecutive patients with ACLF ( n = 192) who met the EASL‐CLIF criteria were retrospectively included. PH severity (hepatic venous pressure gradient, HVPG; platelet count, PLT; and other clinical/radiologic PH surrogates) and SI (white blood cell count; C‐reactive protein [CRP], interleukin‐6) were assessed at the last pre‐ACLF visit, ACLF diagnosis (D0), and after 7 (D7), 28 (D28), and 90 (D90) days. Results: All patients had clinical/radiological signs of PH, and 91 (47%) patients developed ACLF grade 1, 62 (32%) ACLF‐2, and 39 (21%) ACLF‐3. Patients with different D0‐ACLF grades showed similar SI biomarker levels pre‐ACLF, whereas these increased significantly during ACLF. Median PLT decreased in parallel with the ACLF grade and from D0 (ACLF‐3:72; vs. ACLF‐2:81; vs. ACLF‐1:91 G/L; p = 0.094) to D7 (ACLF‐3:39 vs. ACLF‐2:64; vs. ACLF‐1:89 G/L; p < 0.001). In multivariable Cox regression models, D0‐PLT (aHR: 0.96 per 10 G/L [95% CI: 0.93–0.99], p = 0.015) independently predicted D28 mortality. A logistic regression model including sex, D0‐PLT, D0‐CRP, and CLIF‐C ACLF score predicted D28 mortality (AUROC: 0.79 [0.73–0.86]; p < 0.001) and outperformed ( p = 0.036) the MELD‐Na score (AUROC: 0.71 [0.63–0.78]; p < 0.001). Conclusions: Although PH is a necessary condition for ACLF development, underlying PH severity does not confer a risk for higher ACLF severity but impacts survival after ACLF resolution. PLT emerged as a predictor of D28 mortality, independent of the CLIF‐C ACLF score.

14 June 2026 in Scientific Reports
Verified
Journal Article
Open access
PKPhilipp Königshofer
Philipp Königshofer
KBKsenia Brusilovskaya
Ksenia Brusilovskaya
BHBenedikt Silvester Hofer
Benedikt Silvester Hofer
OPOleksandr Petrenko
Oleksandr Petrenko
BSBenedikt Simbrunner
Benedikt Simbrunner
TRThomas Reiberger
Thomas Reiberger
Characterization of toxin-induced mouse models of regressive liver disease, focusing on the detecting of a suitable therapeutic window during fibrosis and portal hypertension (PH) regression. C57BL/6JRj mice were studied when exposed to thioacetamide (TAA) or carbon tetrachloride (CCl4) for 8 or 12 weeks (8w/12w) and after one/two (+R1/+R2) week(s) of TAA/CCl4-free regression. Healthy controls received NaCl or olive oil (OO). Primary readouts included liver fibrosis (collagen proportionate area, CPA), portal pressure (PP), serum transaminases and hepatic fibrosis-related gene expression. The diseased models (8wTAA/12wTAA/8wCCl4/12wCCl4) showed significant fibrosis (CPA: 3.03/3.87/8.53/16.90%; vs. NaCl/OO: 0.87/1.15%) and PH (PP: 6.8/7.7/8.5/10.0 mmHg; vs. NaCl/OO: 5.5/5.1 mmHg). CPA significantly regressed in 8wTAA+R1 (2.60%; p = 0.01) and 12wCCl4+R1 (10.9%; p = 0.01), but not in 12wTAA+R1/8wCCl4+R1. CPA regression was significant in all +R2-groups (p < 0.001) but not in 8wCCl4+R2 (p = 0.30). Significant PP regression was found at 8wCCl4+R1 (5.8 mmHg; p = 0.004) and 12wCCl4+R1 (8.4 mmHg; p = 0.01), but not in the 8w/12w TAA models. All +R2-groups showed significant PP regression: 8wTAA+R2 (6.0 mmHg; p ≤ 0.001), 12wTAA+R2 (6.0 mmHg), 8wCCl4+R2 (6.0 mmHg, p = 0.004) and 12wCCl4+R2 (7.9 mmHg, p = 0.008). Serum AST/ALT levels at +R1/+R2 returned to levels of healthy controls. Hepatic Col1a1 and Timp1 gene expression peaked in 12w-groups and showed a gradual decrease at +R1/+R2: Col1a1 (12wTAA+R1/+R2: -14%/-29%, p = 0.002; 12wCCl4+R1/R2: -28%/-23%, p = 0.05) and Timp1 (12wTAA+R1/+R2: -41%/-61%, p ≤ 0.001; 12wCCl4+R1/R2: -43%/-40%, p ≤ 0.001). While liver disease regressed in all models/timepoints, both liver fibrosis (CPA) and PP remained increased in the 12wCCl4+R1/R2 settings - qualifying this model as suitable for pre-clinical testing of therapeutic strategies aimed at promoting liver fibrosis and PH regression.